PulmatrixPULM
About: Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Employees: 2
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
300% more capital invested
Capital invested by funds: $566K [Q3] → $2.26M (+$1.7M) [Q4]
1.64% more ownership
Funds ownership: 7.25% [Q3] → 8.89% (+1.64%) [Q4]
15% less funds holding
Funds holding: 13 [Q3] → 11 (-2) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for PULM.
Financial journalist opinion









